Answers are grounded in this paper and cite their sources.
In a recently prepublished letter in Lancet Regional Health Southeast Asia,1Mehta P. Time for newer approach in age-old AIHA.Lancet Reg Health Southeast Asia. 2024; 23: 100378https://doi.org/10.1016/j.lansea.2024.100378Summary Full Text Full Text PDF Scopus (0) Google Scholar Pallavi Mehta comments on our viewpoint article titled "Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward."2Datta S.S. Berentsen S. Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward.Lancet Reg Health Southeast Asia. 2023; 23: 100343https://doi.org/10.1016/j.lansea.2023.100343Summary Full Text Full Text PDF Scopus (2) Google Scholar We want to thank Dr. Mehta for commenting, as part of the intention of our article was to create discussion, which might contribute to improvement of clinical practice. However, we disagree with the suggestion of using daratumumab in the second line in warm-antibody autoimmune haemolytic anaemia (wAIHA). In Dr. Mehta's clinical experience, daratumumab has produced a 100% remission rate even after the first dose; number of patients and response criteria not mentioned.1Mehta P. Time for newer approach in age-old AIHA.Lancet Reg Health Southeast Asia. 2024; 23: 100378https://doi.org/10.1016/j.lansea.2024.100378Summary Full Text Full Text PDF Scopus (0) Google Scholar The use of daratumumab in this setting was first reported by Schuetz and colleagues, who described 2 patients with life-threatening wAIHA after stem cell transplantation who were successfully treated with daratumumab and a third patient who suffered a lethal relapse.3Schuetz C. Hoenig M. Moshous D. et al.Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.Blood Adv. 2018; 2: 2550-2553Crossref PubMed Scopus (80) Google Scholar Two case observations have been published on successful daratumumab therapy for refractory cold agglutinin disease (CAD).4Tomkins O. Berentsen S. Arulogun S. Sekhar M. D'Sa S. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy.Am J Hematol. 2020; 95: E293-E295Crossref Scopus (19) Google Scholar,5Zaninoni A. Giannotta J. Galli A. et al.The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease.Front Immunol. 2021; 12: 649441https://doi.org/10.3389/fimmu.2021.649441Crossref Scopus (21) Google Scholar Also cited by Dr. Mehta, a French retrospective series on daratumumab in autoimmune cytopenias reported response in 1 of 2 patients with wAIHA and Evans' syndrome.6Crickx E. Audia S. Robbins A. et al.Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia.Haematologica. 2021; 106: 3198-3201Crossref PubMed Scopus (22) Google Scholar As single case reports are prone to publication bias, these data hardly give any indication on response rates or frequency of toxicity. More reliable data can be derived from a recent, multinational retrospective study of 19 patients treated with daratumumab for refractory wAIHA (n = 12) or CAD (n = 7).7Jalink M. Jacobs C.F. Khwaja J. et al.Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.Blood Adv. 2024; (online ahead of print)https://doi.org/10.1182/bloodadvances.2024012585Crossref Google Scholar In this cohort, 6/12 patients with wAIHA had a response with a modest median response duration at 5.5 months (range, 2–12 months), while 3/7 patients with CAD experienced a sustained response. Furthermore, administering daratumumab on the background of warm autoantibodies could make pre-transfusion testing even more challenging in resource-constraint settings due to limited access to the mitigation strategies, which may cause delay in transfusion.8Biswas D. Basu D. Nag A. Kumar J. Datta S.S. A brief report on pre-transfusion testing in patients receiving the anti-CD38 monoclonal antibody for hematological disorders in India.Indian J Hematol Blood Transfus. 2024; (online ahead of print)https://doi.org/10.1007/s12288-024-01763-5Crossref Scopus (0) Google Scholar Finally, regarding its use in low-to-middle income countries, daratumumab is even more expensive than rituximab. Based on these results, daratumumab can be considered as an option for rescue therapy in patients with multirefractory wAIHA or CAD, but not as a second-line therapy.
No takes yet. Share an insight, caveat, or question.
Berentsen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: